Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This consensus provides a framework for standardized diagnosis and treatment of alopecia areata in the Asia Pacific region, recommending specific therapies based on age and disease severity.

In this study, dihydroartemisinin reduced prostate enlargement and related markers in a rat model of benign prostatic hyperplasia, suggesting its potential as a therapeutic agent.

This study found a significant association between antigliadin antibodies (IgA and IgG) and alopecia areata severity, suggesting a need for celiac disease screening in these patients.

In this retrospective study of 123 pediatric alopecia areata patients, hair loss episodes were most frequent in winter and showed significant correlations with air pressure and hours of sunlight, especially in non-atopic individuals, suggesting a role for climate factors in seasonal hair loss patterns.

This case series found that combining ablative fractional resurfacing and acoustic pressure ultrasound with triamcinolone treatment led to complete recovery in patients with areata alopecia.

Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.

In this study, ALA-PDT significantly reduced lipogenesis in an acne-like model by upregulating OLR1 and suppressing lipid accumulation, highlighting a potential therapeutic target.

This study found that ChatGPT 4.0 and Gemini 1.5 Flash provided more accurate and user-friendly responses to androgenetic alopecia questions than Deepseek R1, suggesting they could be effective tools for patient education with physician guidance.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

This study explores how children perceive peers with alopecia areata and the social effects associated with the condition, but it reports no new experimental findings.

This study reported that patients with alopecia areata experienced significant increases in work productivity loss and activity impairment due to worsening emotional symptoms, highlighting a need for better treatments.

This study characterized Eclipta alba for use in a capillary product for alopecia, confirming its suitable physico-chemical properties and pharmacological constituents, including wedelolactone for hair growth.

This study reported that etrasimod did not achieve significant improvements in hair regrowth for moderate to severe alopecia areata at 24 weeks, although it showed a dose-dependent trend and was safe and well-tolerated over 52 weeks.

In this study, adding intralesional platelet rich plasma to topical mometasone proved more effective and showed earlier improvement in treating alopecia areata compared to using topical mometasone alone.

This study of patients with moderate to severe alopecia areata in Morocco found that oral betamethasone mini-pulses yielded ≥50% hair regrowth in 62.5% of cases, improved quality of life scores, and were generally well-tolerated, though relapses and mild side effects were noted.

This study developed a new neural network model (AA-GAN-AB-MTEDeep) to enhance Alopecia Areata classification using synthetic scalp images, achieving an accuracy of 96.94%.

This study found that in mice with alopecia areata, CD8+ T cells showed clonal expansion and specific regulatory networks, which might help identify new therapeutic targets for patients not responding to JAK inhibitors.

This study found that albumin-bound paclitaxel combined with nedaplatin shows promise as neoadjuvant therapy for esophageal squamous cell carcinoma, achieving a high complete response rate with manageable side effects.

This study describes "alarm reaction" histologic changes in pilosebaceous structures, including regression of hair matrix and alterations in sebaceous glands, affecting follicular and sebaceous gland morphology.

This study identified multiple factors affecting the severity of alopecia areata, suggesting they could inform a tool for measuring disease impact and guide treatment selection.

In this study, despite most patients recognizing alopecia areata as serious and adhering to treatment, psychological well-being remained adversely affected by the disease, highlighting the need for larger studies to better address these psychological impacts.

In this case report, a patient with a history of discoid lupus erythematosus experienced an exacerbation of the condition after topical immunotherapy for alopecia areata, suggesting contact dermatitis as a potential trigger.

This study found that the Alopecia Areata Patient Priority Outcomes questionnaire is a reliable and valid tool for measuring the severity and impact of hair loss in individuals with alopecia areata.

This study found that serum IL-17A levels were significantly higher in patients with alopecia areata compared to healthy controls and correlated with disease severity and activity.

This report describes two cases where topical squaric acid dibutylester application in alopecia totalis patients led to severe pustular lesions, necessitating systemic prednisolone treatment.

New therapy helps treat hair loss.

This abstract provides no clinical results; it describes terms and navigation options for the JAMA network and its publications.

This study suggests that elevated levels of IL-17A and IL-23 in alopecia areata may play roles in disease severity and activity, providing insights into potential therapeutic targets.

This article discusses advancements and methodologies in epitope identification for autoimmune diseases, specifically alopecia areata, but does not report new experimental results.